Sodium-glucose cotransporter 2 (SGLT2) inhibitors, known for conferring both nephroprotective and CV benefits in patients with CKD, irrespective of diabetic status [181], also exhibit anti-inflammatory effects. The gene discussed is SLC5A2; the disease is chronic kidney disease.